aldosterone has been researched along with benidipine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akizuki, O; Inayoshi, A; Kitayama, T; Kusaka, H; Matsubara, M; Sasaki, K; Shirakura, S; Yao, K | 1 |
| Hirayama, K; Kitayama, T; Kosaka, H; Kusaka, H; Matsubara, M; Sasaki, K; Yoda, N | 1 |
| Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M | 1 |
| Furusho, H; Kaneko, S; Kitano, K; Ohtani, K; Okajima, M; Takamura, M; Takashima, S; Usui, S; Yamamoto, K | 1 |
| Hirayama, A; Nagao, K; Takahashi, A; Tani, S | 1 |
2 trial(s) available for aldosterone and benidipine
| Article | Year |
|---|---|
Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Chronic Disease; Diabetic Nephropathies; Dihydropyridines; Female; Glomerular Filtration Rate; Glomerulonephritis; Humans; Hypertension; Male; Middle Aged; Nephrosclerosis; Potassium; Severity of Illness Index; Sodium | 2011 |
Effects of the T/L-type calcium channel blocker benidipine on albuminuria and plasma aldosterone concentration. A pilot study involving switching from L-type calcium channel blockers to benidipine.
Topics: Aged; Albuminuria; Aldosterone; Blood Pressure; Calcium Channel Blockers; Creatinine; Dihydropyridines; Female; Glomerular Filtration Rate; Humans; Hypertension; Male; Middle Aged; Pilot Projects; Prospective Studies; Renin | 2014 |
3 other study(ies) available for aldosterone and benidipine
| Article | Year |
|---|---|
Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
Topics: Adrenal Cortex; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cell Line; Cytochrome P-450 CYP11B2; Dihydropyridines; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Humans; Membrane Potentials; Patch-Clamp Techniques; Potassium Chloride; RNA, Messenger; Steroid 11-beta-Hydroxylase; Tetrazoles; Valine; Valsartan | 2008 |
The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.
Topics: Aldosterone; Binding Sites; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Calcium Channels, T-Type; Cell Line; Dihydropyridines; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Models, Molecular; Molecular Conformation; Mutation; Pyridines; Receptors, Mineralocorticoid; Spironolactone; Stereoisomerism | 2010 |
Benidipine reduces ischemia reperfusion-induced systemic oxidative stress through suppression of aldosterone production in mice.
Topics: Aldosterone; Animals; Apoptosis; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Down-Regulation; Hemodynamics; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Oxidative Stress; Ventricular Dysfunction, Left | 2012 |